Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.

about

Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.

Item

http://www.wikidata.org/entity/Q38954109

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.

@en

type

Item

label

Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.

@en

prefLabel

Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.

@en

P1476

Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.

@en

P2093

Baralee Punyawudho

http://www.w3.org/2001/XMLSchema#string

David M Burger

http://www.w3.org/2001/XMLSchema#string

Kiat Ruxrungtham

http://www.w3.org/2001/XMLSchema#string

Narukjaporn Thammajaruk

http://www.w3.org/2001/XMLSchema#string

Theera Dalodom

http://www.w3.org/2001/XMLSchema#string

P2860

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability

Raltegravir: the first HIV type 1 integrase inhibitor

Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry.

Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.

Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda.

A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.

P304

1583-1595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17512433.2016.1235972

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stephen J. Kerr

Noppaket Singkham

P577

2016-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27626677

http://www.w3.org/2001/XMLSchema#string